Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TIGIT
Biotech
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies.
James Waldron
Jun 13, 2025 8:00am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
Adios, iTeos: Biotech folds weeks after GSK TIGIT termination
May 28, 2025 9:19am
GSK axes $625M TIGIT drug as midphase data disappoint
May 13, 2025 9:44am
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
Apr 3, 2025 8:05am
What were the biggest clinical trial flops of 2024?
Feb 21, 2025 9:00am
